Gilead Sciences, Inc. (NASDAQ:GILD) Expected to Post Q3 2022 Earnings of $1.57 Per Share

Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) – Research analysts at Jefferies Financial Group increased their Q3 2022 earnings estimates for shares of Gilead Sciences in a note issued to investors on Tuesday, August 2nd. Jefferies Financial Group analyst M. Yee now expects that the biopharmaceutical company will earn $1.57 per share for the quarter, up from their prior estimate of $1.51. The consensus estimate for Gilead Sciences’ current full-year earnings is $6.60 per share. Jefferies Financial Group also issued estimates for Gilead Sciences’ Q4 2022 earnings at $1.36 EPS, Q1 2023 earnings at $1.59 EPS, Q2 2023 earnings at $1.59 EPS and Q3 2023 earnings at $1.60 EPS.

A number of other research analysts also recently weighed in on the stock. SVB Leerink began coverage on shares of Gilead Sciences in a research report on Monday, May 23rd. They set a “market perform” rating and a $68.00 target price for the company. TheStreet downgraded shares of Gilead Sciences from a “b-” rating to a “c+” rating in a research report on Friday, July 1st. Royal Bank of Canada increased their target price on shares of Gilead Sciences from $76.00 to $77.00 and gave the company an “outperform” rating in a research report on Tuesday, April 12th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, July 12th. They set a “neutral” rating and a $70.00 target price for the company. Finally, BMO Capital Markets began coverage on shares of Gilead Sciences in a research report on Tuesday, June 7th. They set a “hold” rating and a $63.00 target price for the company. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $72.07.

Gilead Sciences Stock Down 0.6 %

Gilead Sciences stock opened at $61.91 on Thursday. Gilead Sciences has a twelve month low of $57.17 and a twelve month high of $74.12. The firm has a 50 day moving average price of $61.63 and a 200-day moving average price of $61.99. The company has a market capitalization of $77.65 billion, a P/E ratio of 18.88, a P/E/G ratio of 0.60 and a beta of 0.34. The company has a quick ratio of 1.30, a current ratio of 1.48 and a debt-to-equity ratio of 1.31.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Thursday, September 15th will be paid a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 4.72%. The ex-dividend date of this dividend is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is presently 89.02%.

Institutional Trading of Gilead Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Trust Investment Advisors lifted its stake in Gilead Sciences by 1.3% in the 4th quarter. Trust Investment Advisors now owns 12,243 shares of the biopharmaceutical company’s stock worth $889,000 after purchasing an additional 153 shares in the last quarter. Aberdeen Wealth Management LLC raised its position in shares of Gilead Sciences by 2.1% during the 1st quarter. Aberdeen Wealth Management LLC now owns 8,101 shares of the biopharmaceutical company’s stock valued at $482,000 after buying an additional 164 shares in the last quarter. Simmons Bank raised its position in shares of Gilead Sciences by 0.4% during the 1st quarter. Simmons Bank now owns 41,962 shares of the biopharmaceutical company’s stock valued at $2,494,000 after buying an additional 166 shares in the last quarter. MFA Wealth Advisors LLC raised its position in shares of Gilead Sciences by 0.8% during the 4th quarter. MFA Wealth Advisors LLC now owns 20,095 shares of the biopharmaceutical company’s stock valued at $1,458,000 after buying an additional 167 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV raised its position in shares of Gilead Sciences by 13.0% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 1,470 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 169 shares in the last quarter. 80.16% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Stories

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.